SPOTLIGHT: Sepracor licenses epilepsy drug rights


Sepracor is shelling out $75 million up front to license the marketing rights for an experimental epilepsy drug from Portugal's Bial. Sepracor will pay up to $100 million more in developmental and regulatory milestones. Release